| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.05 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.059 | 0.05 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.05 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.05 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.06 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | 0.24 | 0.06 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.06 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.079 | 0.06 |